Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics, Inc. is the subject of a Schedule 13G/A disclosing institutional holdings in its common stock. Janus Henderson Group plc reports beneficial ownership of 4,102,620 shares, representing 10.6% of the class, with shared voting and dispositive power over those shares. A related vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports beneficial ownership of 3,512,932 shares, or 9.1%. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure includes a power of attorney authorizing certain compliance officers to file required reports.
Protara Therapeutics, Inc. filed a Form S-8 to register an additional 2,800,000 shares of common stock for issuance under its 2024 Equity Incentive Plan, following a board amendment adopted on April 17, 2025 and stockholder approval at the annual meeting on June 11, 2025. The filing incorporates by reference the company’s prior Form S-8 (filed August 6, 2024) and specified SEC reports, including the Annual Report filed March 5, 2025 and Quarterly Reports filed May 8, 2025 and August 11, 2025.
The registration statement discloses corporate governance items such as indemnification provisions and the inclusion of a DGCL 102(b)(7) limitation on director liability in the certificate of incorporation, and indicates the company is a non-accelerated filer and a smaller reporting company.
Protara Therapeutics is a clinical-stage biopharmaceutical company advancing TARA-002 (cell therapy) and IV Choline Chloride (intravenous choline) and has no product revenues. For the six months ended June 30, 2025 the company reported a net loss of $26.9 million versus $20.6 million in the prior year period, driven by higher research and development and general and administrative expenses. Cash and cash equivalents declined to $31.5 million while marketable debt securities increased after purchases, leaving $145.6 million in unrestricted cash and marketable securities and $115.3 million in working capital, which management states is sufficient for at least twelve months.
The company highlighted clinical progress: interim ADVANCED-2 data showed high complete response rates in small cohorts (BCG-Unresponsive 100% any-time CR 5/5; BCG-Naive 76% any-time CR 16/21) with mostly Grade 1 adverse events and no Grade 3+ treatment-related events. IV Choline Chloride received FDA Fast Track and orphan considerations and patents through 2041; Protara plans to initiate the THRIVE-3 registrational trial in Q3 2025 and obtained EU-CTR approval in July 2025. Recent financings include a December 2024 public offering (gross ~$100.1M, net ~$93.4M) and an April 2024 private placement (net ~$41.96M). The company notes it will need additional capital to fully execute its clinical plans.
On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.